Details
Stereochemistry | ACHIRAL |
Molecular Formula | C16H13ClN2O2 |
Molecular Weight | 300.7402 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1c2ccc(cc2N(c3ccccc3)C(=O)CC1=O)Cl
InChI
InChIKey=CXOXHMZGEKVPMT-UHFFFAOYSA-N
InChI=1S/C16H13ClN2O2/c1-18-13-8-7-11(17)9-14(13)19(16(21)10-15(18)20)12-5-3-2-4-6-12/h2-9H,10H2,1H3
Molecular Formula | C16H13ClN2O2 |
Molecular Weight | 300.7402 |
Charge | 0 |
Count |
|
Stereochemistry | ACHIRAL |
Additional Stereochemistry | No |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Optical Activity | NONE |
DescriptionCurator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/clobazam.html; http://www.epilepsy.com/medications/clobazam https://www.ncbi.nlm.nih.gov/pubmed/?term=23318278
Curator's Comment:: Description was created based on several sources, including https://www.drugs.com/cdi/clobazam.html; http://www.epilepsy.com/medications/clobazam https://www.ncbi.nlm.nih.gov/pubmed/?term=23318278
Clobazam belongs to the 1,5-benzodiazepine class of drugs with antiepileptic properties. It has been used to treat anxiety and epilepsy since 1970s. In the US clobazam was approved for marketing in October of 2011 for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome. It is also approved for adjunctive therapy for epilepsy in patients who have not responded to first-line drugs and in children who are refractory to first-line drugs. The mechanism of action for clobazam is not fully understood but is thought to involve what is known as potentiation of GABAergic neurotransmission resulting from binding at a benzodiazepine site at the GABA(A) receptor. Possible side effects: constipation, fever, drowsiness, sedation, ataxia, aggressive behavior, lethargy, drooling, and irritability. Other side effects include: urinary tract infection, pneumonia, cough, dysphagia, dysarthria, bronchitis, insomnia, fatigue, decreased appetite, and increased appetite.
Originator
Sources: https://www.ncbi.nlm.nih.gov/pubmed/35198
Curator's Comment:: Discovery of Clobazam at the Maestretti Research Laboratories was first published in 1969. Maestretti Research Laboratories became part of Sanofi.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: CHEMBL2093872 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22145708 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | ONFI Approved UseIndicated for the adjunctive treatment of seizures associated with Lennox-Gastaut syndrome (LGS) in patients 2 years of age or older. Launch Date1.31915514E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
641 μg/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6529527/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBAZAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
13741 μg × h/L EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/6529527/ |
30 mg single, oral dose: 30 mg route of administration: Oral experiment type: SINGLE co-administered: |
CLOBAZAM plasma | Homo sapiens population: HEALTHY age: ADULT sex: FEMALE / MALE food status: FASTED |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
36 h |
30 mg 1 times / day unknown, oral dose: 30 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
CLOBAZAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
10% |
30 mg 1 times / day unknown, oral dose: 30 mg route of administration: Oral experiment type: UNKNOWN co-administered: |
CLOBAZAM plasma | Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Disc. AE: Somnolence, Depressed mood... Other AEs: Delirium... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Other AEs:Depressed mood (1 patient) Libido decreased (1 patient) Erectile dysfunction (1 patient) Insomnia (1 patient) Dysarthria (1 patient) Unsteady gait (1 patient) Dizziness (1 patient) Delirium (2 patients) Sources: Page: p. 69-70 |
10 mg 2 times / day steady, oral Dose: 10 mg, 2 times / day Route: oral Route: steady Dose: 10 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Disc. AE: Transaminases increased... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Page: p. 69 |
15 mg 2 times / day steady, oral Dose: 15 mg, 2 times / day Route: oral Route: steady Dose: 15 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Disc. AE: Transaminases increased... AEs leading to discontinuation/dose reduction: Transaminases increased (1 patient) Sources: Page: p. 69 |
20 mg 2 times / day steady, oral Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Sources: Page: p. 70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 70 |
Disc. AE: Transaminases increased... AEs leading to discontinuation/dose reduction: Transaminases increased (2 patients) Sources: Page: p. 70 |
60 mg 2 times / day steady, oral Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Disc. AE: Somnolence... AEs leading to discontinuation/dose reduction: Somnolence (1 patient) Sources: Page: p. 69 |
70 mg 2 times / day steady, oral Dose: 70 mg, 2 times / day Route: oral Route: steady Dose: 70 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Disc. AE: Dizziness, Somnolence... AEs leading to discontinuation/dose reduction: Dizziness (1 patient) Sources: Page: p. 69Somnolence (1 patient) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Depressed mood | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Dizziness | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Dysarthria | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Erectile dysfunction | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Insomnia | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Libido decreased | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Somnolence | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Unsteady gait | 1 patient Disc. AE |
80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Delirium | 2 patients | 80 mg 2 times / day steady, oral Highest studied dose Dose: 80 mg, 2 times / day Route: oral Route: steady Dose: 80 mg, 2 times / day Sources: Page: p. 69-70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 69-70 |
Transaminases increased | 1 patient Disc. AE |
10 mg 2 times / day steady, oral Dose: 10 mg, 2 times / day Route: oral Route: steady Dose: 10 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Transaminases increased | 1 patient Disc. AE |
15 mg 2 times / day steady, oral Dose: 15 mg, 2 times / day Route: oral Route: steady Dose: 15 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Transaminases increased | 2 patients Disc. AE |
20 mg 2 times / day steady, oral Dose: 20 mg, 2 times / day Route: oral Route: steady Dose: 20 mg, 2 times / day Sources: Page: p. 70 |
healthy n = 70 Health Status: healthy Population Size: 70 Sources: Page: p. 70 |
Somnolence | 1 patient Disc. AE |
60 mg 2 times / day steady, oral Dose: 60 mg, 2 times / day Route: oral Route: steady Dose: 60 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Dizziness | 1 patient Disc. AE |
70 mg 2 times / day steady, oral Dose: 70 mg, 2 times / day Route: oral Route: steady Dose: 70 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Somnolence | 1 patient Disc. AE |
70 mg 2 times / day steady, oral Dose: 70 mg, 2 times / day Route: oral Route: steady Dose: 70 mg, 2 times / day Sources: Page: p. 69 |
healthy n = 24 Health Status: healthy Population Size: 24 Sources: Page: p. 69 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 17.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | |||
Page: 16.0 |
no | yes (co-administration study) Comment: clobazam increased dextromethorphan cmax 90%, auc 59% Page: 16.0 |
||
Page: 17.0 |
weak | |||
Page: 9.0 |
weak | yes (co-administration study) Comment: clobazam decreased midazolam auc 27%, cmax 24% Page: 9.0 |
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 15.0 |
major | yes (co-administration study) Comment: ketoconazole increased clobazam auc 54%, no effect on cmax Page: 15.0 |
||
Page: 15.0 |
minor | |||
Page: 15.0 |
minor | yes (co-administration study) Comment: omeprazole increased clobazam auc 30-36%, no effect on cmax Page: 15.0 |
||
Page: 96.0 |
no | |||
Page: 17.0 |
yes | yes (co-administration study) Comment: verapamil reduced clobazam transport >96% Page: 17.0 |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Page: 20.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Management strategies for refractory localization-related seizures. | 2001 |
|
Epileptic encephalopathy. | 2001 |
|
[A pharmacological profile of clobazam (Mystan), a new antiepileptic drug]. | 2001 Aug |
|
[Clinical features and treatment of refractory epilepsy in children]. | 2001 Dec |
|
Infantile spasms: diagnosis and assessment of treatment response by video-EEG. | 2001 Oct |
|
Evolution of juvenile myoclonic epilepsy treated from the outset with sodium valproate. | 2001 Sep |
|
Psychosomatic reactions to a stressful environment and an attempt at pharmacological modification. | 2001 Sep-Oct |
|
On the use of tranquillisers in epilepsy. | 2002 |
|
Evidence of polymorphic CYP2C19 involvement in the human metabolism of N-desmethylclobazam. | 2002 Dec |
|
Vagus nerve stimulation in a case of epilepsy with CSWSS: respiratory side effects during sleep. | 2002 Oct |
|
A casuistic rationale for the treatment of spastic and myocloni in a childhood neurodegenerative disease: neuronal ceroid lipofuscinosis of the type Jansky-Bielschowsky. | 2002 Oct-Dec |
|
Direct injection HPLC method for the determination of selected benzodiazepines in plasma using a Hisep column. | 2003 Dec 4 |
|
Mechanism-based pharmacokinetic/pharmacodynamic modeling of the electroencephalogram effects of GABAA receptor modulators: in vitro-in vivo correlations. | 2003 Jan |
|
Use of clobazam for the treatment of refractory complex partial seizures. | 2003 Jul |
|
Screening, library-assisted identification and validated quantification of 23 benzodiazepines, flumazenil, zaleplone, zolpidem and zopiclone in plasma by liquid chromatography/mass spectrometry with atmospheric pressure chemical ionization. | 2004 Aug |
|
Unusual side-effects due to clobazam: a case report with genetic study of CYP2C19. | 2004 Jan |
|
Sporadic major hyperekplexia in neonates and infants: clinical manifestations and outcome. | 2004 Jul |
|
Pharmacodynamic interaction studies with topiramate in the pentylenetetrazol and maximal electroshock seizure models. | 2004 Jul |
|
Forensic intoxication with clobazam: HPLC/DAD/MSD analysis. | 2004 Jul 16 |
|
In vitro characterization of clobazam metabolism by recombinant cytochrome P450 enzymes: importance of CYP2C19. | 2004 Nov |
|
Affinity of various benzodiazepine site ligands in mice with a point mutation in the GABA(A) receptor gamma2 subunit. | 2004 Oct 15 |
|
The difficulty in diagnosing non-convulsive status epilepticus during routine medical practice. | 2004 Sep |
|
Management of Landau-Kleffner syndrome. | 2005 |
|
Properties of antiepileptic drugs in the treatment of idiopathic generalized epilepsies. | 2005 |
|
[Subacute encephalitis with anti-glutamate receptor antibodies presented with epilepsia partialis continua]. | 2005 Aug |
|
Molecular regulation of glutamate and GABA transporter proteins by clobazam during epileptogenesis in Fe(+++)-induced epileptic rats. | 2005 Dec 14 |
|
Intermittent clobazam therapy in febrile seizures. | 2005 Jan |
|
Stiripentol. | 2005 Jul |
|
Neuroembryopathic effect of clobazam in rat: a histological study. | 2005 Jun |
|
Visually self-induced seizures sensitive to round objects. | 2005 May |
|
Screening method for benzodiazepines and hypnotics in hair at pg/mg level by liquid chromatography-mass spectrometry/mass spectrometry. | 2005 Oct 15 |
|
Levetiracetam in idiopathic generalised epilepsy and porphyria cutanea tarda. | 2006 |
|
Stiripentol, a putative antiepileptic drug, enhances the duration of opening of GABA-A receptor channels. | 2006 Apr |
|
In vitro and in vivo inhibitory effect of stiripentol on clobazam metabolism. | 2006 Apr |
|
Landau-Kleffner syndrome is not an eponymic badge of ignorance. | 2006 Aug |
|
Effects of some antiepileptics on septal-kindled seizures in rats. | 2006 Dec |
|
[Epilepsy: which therapy in acute care?]. | 2006 Dec 8 |
|
Anticonvulsant hypersensitivity syndrome to lamotrigine confirmed by lymphocyte stimulation in vitro. | 2006 Feb |
|
Pharmacological properties of GABAA receptors containing gamma1 subunits. | 2006 Feb |
|
Eye rolling as a manifestation of clobazam toxicity in a child with epilepsy. | 2006 Jul |
|
Safety and efficacy of clobazam versus phenytoin-sodium in the antiepileptic drug treatment of solitary cysticercus granulomas. | 2006 Jun |
|
Benign angiopathy of the central nervous system associated with phenytoin intoxication. | 2006 Jun |
|
Abusive prescription of psychostimulants: a study of two cases. | 2006 Mar |
|
Oxidative stress in children receiving valproic acid. | 2006 Nov |
|
Quantification of benzodiazepines in whole blood and serum. | 2006 Nov |
|
Treatment in the pediatric emergency department is evidence based: a retrospective analysis. | 2006 Oct 6 |
|
Effectiveness of clobazam as add-on therapy in children with refractory focal epilepsy. | 2006 Sep |
|
The detection of sedatives in hair and nail samples using tandem LC-MS-MS. | 2007 Feb 14 |
|
Clobazam. | 2007 Jan |
|
Stiripentol. | 2007 Jan |
Sample Use Guides
Patients ≤30 kg body weight: Initiate at 5 mg daily and titrate as tolerated up to 20 mg daily. Patients > 30 kg body weight: Initiate at 10 mg daily and titrate as tolerated up to 40 mg daily. For doses above 5 mg/day administer in two divided doses. Dosage adjustment needed in following groups: Geriatric patients. Known CYP2C19 poor metabolizers. Mild or moderate hepatic impairment; no information for severe hepatic impairment.
Route of Administration:
Oral
In Vitro Use Guide
Sources: http://www.ncbi.nlm.nih.gov/pubmed/14636342
Recurrent ictal-like seizures (ILEs, four per hour) were generated in intact corticohippocampal formations (CHFs) of P7-8 rats, and extracellular recordings were performed in the hippocampus and neocortex. Clobazam was applied at clinically relevant concentrations (at least two), during 30 min after the third ILE. Clobazam prevented the occurrence of seizures in recurrent ictal-like seizures.
Substance Class |
Chemical
Created
by
admin
on
Edited
Fri Jun 25 21:15:48 UTC 2021
by
admin
on
Fri Jun 25 21:15:48 UTC 2021
|
Record UNII |
2MRO291B4U
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Brand Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
2751
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
||
|
FDA ORPHAN DRUG |
248307
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
||
|
LIVERTOX |
218
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
||
|
WHO-ATC |
N05BA09
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
||
|
NCI_THESAURUS |
C28197
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
||
|
WHO-VATC |
QN05BA09
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
||
|
NDF-RT |
N0000175694
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
22316-47-8
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
CLOBAZAM
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
C012255
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
22316-47-8
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
2789
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
3055
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
DB00349
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
SUB06673MIG
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
CHEMBL70418
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
8343
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
2MRO291B4U
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
C81615
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
244-908-7
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
Clobazam
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
21241
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | RxNorm | ||
|
M3626
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | Merck Index | ||
|
N0000182137
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | Cytochrome P450 2D6 Inhibitors [MoA] | ||
|
7149
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY | |||
|
682
Created by
admin on Fri Jun 25 21:15:48 UTC 2021 , Edited by admin on Fri Jun 25 21:15:48 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLIC ENZYME -> INDUCER | |||
|
BINDER->LIGAND |
BINDING
|
||
|
EXCRETED UNCHANGED |
FECAL
|
||
|
EXCRETED UNCHANGED |
Clobazam is cleared mainly by metabolism with subsequent renal elimination of metabolites. In a mass balance study, 82% of the dose administered was recovered in the urine and 11% in the feces. Clobazam represents ~2 % of the dose recovered in urine.
URINE
|
||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
TRANSPORTER -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE |
MAJOR
|
||
|
METABOLIC ENZYME -> SUBSTRATE |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE -> PARENT | |||
|
METABOLITE ACTIVE -> PARENT | |||
|
METABOLITE -> PARENT | |||
|
METABOLITE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
IMPURITY -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Biological Half-life | PHARMACOKINETIC |
|
|
|||
Volume of Distribution | PHARMACOKINETIC |
|
|
|||
Tmax | PHARMACOKINETIC |
|
SINGLE- OR MULTIPLE-DOSE ADMINISTRATIONS |
|
||